We found that the pan-BET pharmacological inhibitor JQ1 was able to promote a differentiation program in GBM cells, likely toward a neuronal-like phenotype, thus impairing cell proliferation and sensitizing cells to the drug Temozolomide (TMZ). This evidence concerns the gene DNER and glioblastoma.